Molecular targets and mechanisms involved in the action of Banxia Shumi decoction in insomnia treatment
Authors:
Open Access
- 10 March 2023
- journal article
- research article
- Published by Wolters Kluwer Health in Medicine
- Vol. 102 (10) , e33229
Abstract
Insomnia is a common sleep-wake rhythm disorder, which is closely associated with the occurrence of many serious diseases. Recent researches suggest that circadian rhythms play an important role in regulating sleep duration and sleep quality. Banxia Shumi decoction (BSXM) is a well-known Chinese formula used to treat insomnia in China. However, the overall molecular mechanism behind this therapeutic effect has not yet been fully elucidated. This study aimed to identify the molecular targets and mechanisms involved in the action of BSXM during the treatment of insomnia. Using network pharmacology and molecular docking methods, we investigated the molecular targets and underlying mechanisms of action of BSXM in insomnia therapy. We identified 8 active compounds from Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform and the traditional Chinese medicine integrative database that corresponded to 26 target genes involved in insomnia treatment. The compound-differentially expressed genes of the BXSM network indicated that cavidine and gondoic acid could potentially become key components of drugs used for insomnia treatment. Further analysis revealed that GSK3B, MAPK14, IGF1R, CCL5, and BCL2L11 were core targets significantly associated with the circadian clock. Pathway enrichment analysis of Kyoto Encyclopedia of Genes and Genomes revealed that epidermal growth factor receptor tyrosine kinase inhibitor resistance was the most prominently enriched pathway for BSXM in the insomnia treatment. The forkhead box O signaling pathway was also found to be significantly enriched. These targets were validated using the Gene Expression Omnibus dataset. Molecular docking studies were performed to confirm the binding of cavidine and gondoic acid to the identified core targets. To our knowledge, our study confirmed for the first time that the multi-component, multi-target, and multi-pathway characteristics of BXSM may be the potential mechanism for treating insomnia with respect to the circadian clock gene. The results of this study provided theoretical guidance for researchers to further explore its mechanism of action.Keywords
This publication has 60 references indexed in Scilit:
- The neurobiology, investigation, and treatment of chronic insomniaThe Lancet Neurology, 2015
- The Pathophysiology of InsomniaChest, 2015
- Targeting Human Central Nervous System Protein Kinases: An Isoform Selective p38αMAPK Inhibitor That Attenuates Disease Progression in Alzheimer’s Disease Mouse ModelsACS Chemical Neuroscience, 2015
- TCMSP: a database of systems pharmacology for drug discovery from herbal medicinesJournal of Cheminformatics, 2014
- Combining Machine Learning Systems and Multiple Docking Simulation Packages to Improve Docking Prediction Reliability for Network PharmacologyPLOS ONE, 2013
- A role for clock genes in sleep homeostasisCurrent Opinion in Neurobiology, 2013
- TCMID: traditional Chinese medicine integrative database for herb molecular mechanism analysisNucleic Acids Research, 2012
- FOXO3-induced reactive oxygen species are regulated by BCL2L11 (Bim) and SESN3Journal of Cell Science, 2012
- The harmala alkaloid harmine is a modulator of circadian Bmal1 transcriptionBioscience Reports, 2011
- pROC: an open-source package for R and S+ to analyze and compare ROC curvesBMC Bioinformatics, 2011